{"id":561,"date":"2026-09-04T04:14:57","date_gmt":"2026-09-04T04:14:57","guid":{"rendered":"https:\/\/americaninfusioncare.com\/blogs\/?p=561"},"modified":"2026-09-04T04:15:01","modified_gmt":"2026-09-04T04:15:01","slug":"thyroid-eye-disease-infusion-treatment","status":"publish","type":"post","link":"https:\/\/americaninfusioncare.com\/blogs\/thyroid-eye-disease-infusion-treatment\/","title":{"rendered":"Thyroid Eye Disease Infusion Treatment: What Patients Should Know"},"content":{"rendered":"

Thyroid eye disease (TED), also called Graves\u2019 ophthalmopathy, is an autoimmune condition that affects the tissues around the eyes. It is commonly associated with Graves\u2019 disease, although thyroid eye disease can also occur in people with other autoimmune thyroid conditions. Symptoms may include eye redness, dryness, swelling, pressure, bulging eyes, sensitivity to light, and double vision. In more serious cases, TED can affect vision and significantly impact quality of life.<\/span><\/p>\n

For patients with moderate-to-severe thyroid eye disease, infusion therapy may be an important treatment option. One of the major advances in TED treatment is teprotumumab, an intravenous medication that targets insulin-like growth factor-1 receptor (IGF-1R), a pathway involved in the inflammatory and tissue changes associated with TED. The U.S. Food and Drug Administration currently indicates TEPEZZA (teprotumumab-trbw) for the treatment of thyroid eye disease regardless of disease activity or duration.<\/span><\/p>\n

What Is Thyroid Eye Disease Infusion Treatment?<\/b><\/h2>\n

Thyroid eye disease infusion treatment<\/span><\/a> involves administering medication directly into a vein through an intravenous (IV) infusion. Teprotumumab is given in a series of treatments rather than as a single infusion.<\/span><\/p>\n

According to current FDA prescribing information, the recommended regimen starts with a 10 mg\/kg IV infusion, followed by 20 mg\/kg every three weeks for seven additional infusions, for a total of eight infusions. The infusions are administered over approximately 60 to 90 minutes according to the current label.<\/span><\/p>\n

The goal of treatment is to reduce the underlying disease processes that contribute to symptoms such as proptosis, swelling, and double vision. Clinical research has demonstrated improvement in several signs and symptoms of TED in appropriately selected patients.<\/span><\/p>\n

Who May Benefit From Infusion Therapy?<\/b><\/h2>\n

Not every person with thyroid eye disease needs infusion treatment. Mild TED may often be managed with supportive measures, monitoring, thyroid management, and other approaches depending on the patient’s symptoms.<\/span><\/p>\n

Infusion therapy may be considered when TED causes significant symptoms or functional problems. A healthcare professional may evaluate eye protrusion, inflammation, double vision, eye movement, visual function, disease severity, and other individual factors before recommending treatment.<\/span><\/p>\n

The American Thyroid Association and European Thyroid Association emphasize early diagnosis, timely referral, and coordinated care involving healthcare professionals experienced in thyroid disease and ophthalmology.<\/span><\/p>\n

Patients with chronic or less active disease may also sometimes be considered for teprotumumab. Research has reported improvement in proptosis in patients with long-standing TED and low disease activity, but treatment decisions should be individualized after discussing potential benefits and risks.<\/span><\/p>\n

What Happens During a TED Infusion?<\/b><\/h2>\n

Before treatment, your healthcare team may review your medical history, current medications, thyroid status, eye symptoms, and other health considerations. Depending on your circumstances, additional evaluations or laboratory testing may be recommended.<\/span><\/p>\n

During the infusion, an IV line is placed, and the prescribed medication is administered under medical supervision. Patients are monitored for potential infusion-related reactions. The FDA prescribing information recommends appropriate management if an infusion reaction occurs, including interrupting or slowing the infusion when appropriate.<\/span><\/p>\n

Because treatment is provided as a series of infusions, maintaining scheduled appointments is important. Your healthcare provider can monitor your response throughout the treatment course and determine whether adjustments or additional care are needed.<\/span><\/p>\n

Potential Benefits of Teprotumumab<\/b><\/h2>\n

The primary purpose of thyroid eye disease infusion treatment is to improve clinically significant eye symptoms and reduce the impact of TED on daily life.<\/span><\/p>\n

Studies have found that teprotumumab can improve proptosis, disease activity, symptoms, and certain aspects of visual function in patients with TED. In one clinical study summarized by the American Thyroid Association, 77% of patients receiving teprotumumab achieved improvement in eye bulging compared with 15% of patients receiving no drug.<\/span><\/p>\n

However, individual results can vary. Some patients may experience recurrence or worsening of symptoms after treatment, so ongoing follow-up remains important.<\/span><\/p>\n

Possible Side Effects and Safety Considerations<\/b><\/h2>\n

As with any medical treatment, teprotumumab can cause side effects. Potential concerns include infusion reactions, muscle spasms, nausea, headache, changes in blood glucose, hearing-related problems, and other adverse effects.<\/span><\/p>\n

Blood glucose monitoring may be particularly important for some patients. Recent American Thyroid Association reporting highlights an increased risk of hyperglycemia and recommends continued blood glucose monitoring and risk assessment during treatment.<\/span><\/p>\n

Patients should tell their healthcare provider about existing medical conditions, medications, hearing concerns, blood sugar issues, and any new or worsening symptoms. Your healthcare team can explain the risks and benefits based on your individual situation.<\/span><\/p>\n

Why Early Evaluation Matters<\/b><\/h2>\n

TED can change over time. Early evaluation may help healthcare professionals determine the severity and activity of the disease and develop an appropriate treatment plan.<\/span><\/p>\n

People experiencing new eye bulging, persistent eye redness, swelling, double vision, eye pain, or changes in vision should seek medical evaluation. Severe or sudden vision changes require prompt medical attention.<\/span><\/p>\n

Managing the underlying thyroid condition is also an important part of comprehensive care. Because TED can involve both thyroid and eye-related concerns, collaboration between appropriate specialists can help ensure that treatment decisions address the patient’s overall needs.<\/span><\/p>\n

Choosing a Thyroid Eye Disease Treatment Center<\/b><\/h2>\n

When considering thyroid eye disease infusion treatment, look for a healthcare team that provides careful evaluation, appropriate monitoring, and individualized treatment planning. Ask about the expected number of infusions, monitoring requirements, potential side effects, and what follow-up care will be provided.<\/span><\/p>\n

Infusion treatment is not appropriate for everyone, and treatment decisions should be made with a qualified healthcare professional who understands your medical history and the severity of your TED.<\/span><\/p>\n

Frequently Asked Questions<\/b><\/h2>\n
1. What is thyroid eye disease infusion treatment?<\/b><\/h5>\n

It is an IV-based treatment used to manage thyroid eye disease. Teprotumumab is an FDA-indicated medication for TED and is administered through a series of intravenous infusions.<\/span><\/p>\n

2. How many infusions are needed for thyroid eye disease?<\/b><\/h5>\n

The current FDA-recommended regimen consists of eight infusions: an initial 10 mg\/kg dose followed by seven 20 mg\/kg doses given every three weeks.<\/span><\/p>\n

3. Does teprotumumab treat bulging eyes?<\/b><\/h5>\n

Teprotumumab may reduce proptosis, or eye bulging, in appropriate patients with thyroid eye disease. Clinical studies have demonstrated meaningful improvement in proptosis for some patients.<\/span><\/p>\n

4. Can people with inactive or chronic TED receive infusion treatment?<\/b><\/h5>\n

The current FDA indication covers thyroid eye disease regardless of activity or duration. Clinical research has also found benefits in some patients with long-standing, low-activity disease. Treatment should be individualized.<\/span><\/p>\n

5. Are there side effects from thyroid eye disease infusions?<\/b><\/h5>\n

Yes. Possible adverse effects include infusion reactions, muscle spasms, headache, elevated blood glucose, and hearing-related problems, among others. Your healthcare provider should review the risks before treatment.<\/span><\/p>\n

 <\/p>\n

Schedule a Thyroid Eye Disease Consultation<\/b><\/h3>\n

If thyroid eye disease is affecting your comfort, appearance, eye movement, or vision, professional evaluation can help determine the most appropriate treatment approach. A qualified healthcare team can assess your symptoms and discuss whether infusion therapy or another treatment option may be suitable for you.<\/span><\/p>\n

Visit us <\/span>https:\/\/americaninfusioncare.com\/treatment-and-care\/available-therapies\/<\/span><\/a> to learn more about thyroid eye disease evaluation and available treatment options.<\/span><\/p>\n

Contact us at <\/span>469-305-2361<\/span><\/a> today to schedule a consultation and discuss your symptoms, treatment goals, and next steps.<\/span><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Thyroid eye disease can cause eye swelling, bulging, discomfort, and double vision. Learn how infusion treatment with teprotumumab may help manage symptoms and what patients should expect.<\/p>\n","protected":false},"author":3,"featured_media":562,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-561","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-post"],"_links":{"self":[{"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/posts\/561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/comments?post=561"}],"version-history":[{"count":1,"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/posts\/561\/revisions"}],"predecessor-version":[{"id":563,"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/posts\/561\/revisions\/563"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/media\/562"}],"wp:attachment":[{"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/media?parent=561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/categories?post=561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/americaninfusioncare.com\/blogs\/wp-json\/wp\/v2\/tags?post=561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}